Share on StockTwits

Arena Pharmaceuticals (NASDAQ:ARNA) is scheduled to be releasing its Q114 earnings data on Monday, May 12th. Analysts expect Arena Pharmaceuticals to post earnings of ($0.10) per share and revenue of $7.98 million for the quarter.

Arena Pharmaceuticals (NASDAQ:ARNA) last released its earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.13. The company had revenue of $6.50 million for the quarter, compared to the consensus estimate of $7.00 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 242.1% on a year-over-year basis. On average, analysts expect Arena Pharmaceuticals to post $-0.42 EPS for the current fiscal year and $-0.26 EPS for the next fiscal year.

Arena Pharmaceuticals (NASDAQ:ARNA) opened at 6.98 on Friday. Arena Pharmaceuticals has a one year low of $4.05 and a one year high of $9.25. The stock’s 50-day moving average is $6.35 and its 200-day moving average is $6.1. The company’s market cap is $1.530 billion.

On the ratings front, analysts at Wells Fargo & Co. initiated coverage on shares of Arena Pharmaceuticals in a research note on Thursday, April 24th. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $8.70.

In other Arena Pharmaceuticals news, Director Donald Belcher sold 4,176 shares of the company’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $7.00, for a total transaction of $29,232.00. Following the completion of the transaction, the director now directly owns 68,728 shares in the company, valued at approximately $481,096. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.